Antidepressive Agents

• 

  Subject Areas on Research

  • "A powerful intervention: general practitioners'; use of sickness certification in depression". 
  • 5-HTTLPR and use of antidepressants after colorectal cancer including a meta-analysis of 5-HTTLPR and depression after cancer. 
  • A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction. 
  • A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression: Is there differential effect of ropinirole dose on developing psychotic symptom? 
  • A case study of pooled-studies publications indicated potential for both valuable information and bias. 
  • A combined treatment approach to anxiety in the medically ill. 
  • A comparison of the efficacy of stimulus control for medicated and nonmedicated insomniacs. 
  • A double-blind comparison of bupropion and amitriptyline in depressed inpatients. 
  • A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). 
  • A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression. 
  • A genome-wide association study of antidepressant response in Koreans. 
  • A global logrank test for adaptive treatment strategies based on observational studies. 
  • A history of the concept of atypical depression. 
  • A longitudinal evaluation of adolescent depression and adult obesity. 
  • A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatment. 
  • A preliminary metabolomic analysis of older adults with and without depression. 
  • A prescription for unemployment? Recessions and the demand for mental health drugs. 
  • A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment. 
  • A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. 
  • A randomized controlled trial of paroxetine for noncardiac chest pain. 
  • A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. 
  • A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. 
  • A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression. 
  • A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. 
  • A systematic review of antidepressant placebo-controlled trials for geriatric depression: limitations of current data and directions for the future. 
  • A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. 
  • A systematic review of relations between resting-state functional-MRI and treatment response in major depressive disorder. 
  • A systematic review of the combined use of electroconvulsive therapy and psychotherapy for depression. 
  • A systematic review of treatments for refractory depression in older people. 
  • Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. 
  • Adequacy of antidepressant treatment by psychiatric residents: the antidepressant treatment history form as a possible assessment tool. 
  • Adinazolam sustained-release treatment of panic disorder: a double-blind study. 
  • Adjunctive brexpiprazole for the treatment of major depressive disorder. 
  • Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression. 
  • Advances in Pharmacotherapy of Late-Life Depression. 
  • Advances in opioid antagonist treatment for opioid addiction. 
  • An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials. 
  • An application of the revised CONSORT standards to FDA summary reports of recently approved antidepressants and antipsychotics. 
  • An open-label pilot study of aripiprazole for male and female veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants. 
  • An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial. 
  • An open-label trial of adjunctive oxcarbazepine for bipolar disorder. 
  • An overview of the clinical rationale for advancing gender-related psychopharmacology and drug abuse research. 
  • Angiotensin receptor gene polymorphisms and 2-year change in hyperintense lesion volume in men. 
  • Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. 
  • Antidepressant Regulatory Warnings, Prescription Patterns, Suicidality and Other Aggressive Behaviors in Major Depressive Disorder and Anxiety Disorders. 
  • Antidepressant Use, Depression, and Poor Cardiovascular Outcomes: The Chicken or the Egg?: Comment on "Antidepressant Use and Risk of Incident Cardiovascular Morbidity and Mortality Among Postmenopausal Women in the Women's Health Initiative Study". 
  • Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram. 
  • Antidepressant effects of nicotine in an animal model of depression. 
  • Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review. 
  • Antidepressant medication use [corrected] and risk of ovarian cancer. 
  • Antidepressant medication use in palliative care. 
  • Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. 
  • Antidepressant response to electroconvulsive therapy is sustained after catecholamine depletion. 
  • Antidepressant therapy in patients with ischemic heart disease. 
  • Antidepressant treatment and worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. 
  • Antidepressant treatment practice in the face of STAR*D and STEP-BD. 
  • Antidepressant treatment response in bipolar II disorder. 
  • Antidepressant use and safety in civil aviation: a case-control study of 10 years of Australian data. 
  • Antidepressant use and the risk of myocardial infarction. 
  • Antidepressant use by race. 
  • Antidepressant use in pregnancy and the risk of cardiac defects. 
  • Antidepressant use in the elderly: association with demographic characteristics, health-related factors, and health care utilization. 
  • Antidepressant use, depression, and survival in patients with heart failure. 
  • Antidepressant-like effects of nicotine and reduced nicotinic receptor binding in the Fawn-Hooded rat, an animal model of co-morbid depression and alcoholism. 
  • Antidepressants in chronic pain syndromes. 
  • Antipsychotic drugs for depression? 
  • Are Patients with Childhood Onset of Insomnia and Depression More Difficult to Treat Than Are Those with Adult Onsets of These Disorders? A Report from the TRIAD Study. 
  • Are psychiatrists' characteristics related to how they care for depression in the medically ill? Results from a national case-vignette survey. 
  • Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting. 
  • Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. 
  • Assessing anxious features in depressed outpatients. 
  • Assessing the effect of Measurement-Based Care depression treatment on HIV medication adherence and health outcomes: rationale and design of the SLAM DUNC Study. 
  • Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. 
  • Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. 
  • Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. 
  • Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. 
  • Atypical depression: a comprehensive review. 
  • Autoradiographic quantification of neurochemical markers of serotonin, dopamine and opioid systems in rat brain mesolimbic regions following chronic St John's wort treatment. 
  • Available therapies and current management of fibromyalgia: focusing on pharmacological agents. 
  • Behavioral treatment of obsessive-compulsive neurosis. 
  • Better, Faster, Safer: Exploring Biomarkers of Response to Transform Electroconvulsive Therapy. 
  • Biological and social predictors of long-term geriatric depression outcome. 
  • Biological therapies for posttraumatic stress disorder: an overview. 
  • Bipolar Depression: Pregnancy, Postpartum, and Lactation. 
  • Brain 5-HT deficiency increases stress vulnerability and impairs antidepressant responses following psychosocial stress. 
  • Brain choline in depression: in vivo detection of potential pharmacodynamic effects of antidepressant therapy using hydrogen localized spectroscopy. 
  • Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. 
  • Bringing back melancholia. 
  • Bursts and the efficacy of selective serotonin reuptake inhibitors. 
  • Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives. 
  • Case records of the Massachusetts General Hospital. Case 14-2008. A 78-year-old man with anergia and anhedonia associated with cardiovascular surgery. 
  • Case report of treatment of severe mood disorder in an inpatient setting: when less is more. 
  • Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine. 
  • Case-control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder. 
  • Changes in HIV Outcomes Following Depression Care in a Resource-Limited Setting: Results from a Pilot Study in Bamenda, Cameroon. 
  • Chaperoning epigenetics: FKBP51 decreases the activity of DNMT1 and mediates epigenetic effects of the antidepressant paroxetine. 
  • Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). 
  • Chronic pain and depression. 
  • Cingulum bundle white matter lesions influence antidepressant response in late-life depression: a pilot study. 
  • Clinical and radiological characteristics of early versus late mild cognitive impairment in patients with comorbid depressive disorder. 
  • Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline. 
  • Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression. 
  • Clinical experience with substance P receptor (NK1) antagonists in depression. 
  • Clinical outcomes of older depressed patients with and without comorbid neuroticism. 
  • Clinical trial evidence for treatment of depression in heart failure. 
  • Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. 
  • Cognitive improvement following treatment in late-life depression: relationship to vascular risk and age of onset. 
  • Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. 
  • Comorbidities in patients with all-positive symptoms on sinonasal outcomes test quality-of-life instrument. 
  • Comorbidity and depression treatment. 
  • Comparative antidopaminergic properties of thioridazine, mesoridazine and sulforidazine on the corpus striatum. 
  • Comparative effectiveness of dual vs. single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression. 
  • Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. 
  • Comparison of brain structural variables, neuropsychological factors, and treatment outcome in early-onset versus late-onset late-life depression. 
  • Competing demands: Does care for depression fit in primary care? 
  • Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI-BD. 
  • Concerns about data reporting and interpretation in "Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial". 
  • Consensus statement on depression, anxiety, and oncology. 
  • Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. 
  • Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. 
  • Consensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety. 
  • Contemporary management of comorbid anxiety and depression in geriatric patients. 
  • Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). 
  • Correlates of remission in primary care patients treated for minor depression. 
  • Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression. 
  • Curcumin as a putative antidepressant. 
  • DAOA variants on diagnosis and response to treatment in patients with major depressive disorder and bipolar disorder. 
  • DHEA metabolism to the neurosteroid androsterone: a possible mechanism of DHEA's antidepressant action. 
  • Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. 
  • Datapoints: Use of medications and counseling for depression by Asian and multiple-race adolescents aged 12-17 years. 
  • Defining treatment-resistant depression: a comprehensive review of the literature. 
  • Depression after myocardial infarction. 
  • Depression and antidepressant use after stroke and transient ischemic attack. 
  • Depression and cardiac risk. 
  • Depression and cognition in the elderly. 
  • Depression and insomnia in women. 
  • Depression and insulin resistance: applications to polycystic ovary syndrome. 
  • Depression and ischemic heart disease. 
  • Depression and ischemic heart disease: what have we learned from clinical trials? 
  • Depression and ischemic heart disease: what have we learned so far and what must we do in the future? 
  • Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. 
  • Depression in late life. 
  • Depression in long-term care. 
  • Depression in the elderly. 
  • Depression outcome in inpatients with congestive heart failure. 
  • Depression treatment in a sample of 1,801 depressed older adults in primary care. 
  • Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. 
  • Depression, post-traumatic stress disorder, and dry eye syndrome: a study utilizing the national United States Veterans Affairs administrative database. 
  • Depressive Symptoms and Risk of Cardiovascular Events in Blacks: Findings From the Jackson Heart Study. 
  • Depressive characteristics of FSL rats: involvement of central nicotinic receptors. 
  • Depressive disorders in older medical inpatients. 
  • Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) Study. 
  • Derivation of the SPAN, a brief diagnostic screening test for post-traumatic stress disorder. 
  • Design and baseline data from the Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized controlled trial. 
  • Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms. 
  • Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. 
  • Dexamethasone suppression test and selection of antidepressant medications. 
  • Dexamethasone suppression tests in antidepressant treatment of melancholia. The process of normalization and test-retest reproducibility. 
  • Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. 
  • Diagnostic Accuracy of Screening Tests and Treatment for Post-Acute Coronary Syndrome Depression: A Systematic Review. 
  • Differential effects of the antidepressant mirtazapine on amphetamine- and dizocilpine-induced PPI deficits. 
  • Difficult behaviors in long-term care patients with dementia. 
  • Disparities in Depressive Symptoms and Antidepressant Treatment by Gender and Race/Ethnicity among People Living with HIV in the United States. 
  • Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women. 
  • Does antidepressant therapy improve cognition in elderly depressed patients? 
  • Does medication adherence following a copayment increase differ by disease burden? 
  • Does minocycline have antidepressant effect? 
  • Does neurotropin-3 have a therapeutic implication in major depression? 
  • Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): clinical rationale and design. 
  • Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. 
  • Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. 
  • Duloxetine: an emerging evidence for fibromyalgia. 
  • Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. 
  • Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. 
  • Dysfunctional attitudes in depressed patients before and after clinical treatment and in normal control subjects. 
  • Eating disorders. 
  • Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. 
  • Effect of antidepressant drugs in mice lacking the norepinephrine transporter. 
  • Effect of improving depression care on pain and functional outcomes among older adults with arthritis: a randomized controlled trial. 
  • Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. 
  • Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. 
  • Effectiveness of chromium in atypical depression: a placebo-controlled trial. 
  • Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder: An Open-Label, Flexible-Dose, Exploratory Study. 
  • Effects of a Course of Right Unilateral Ultrabrief Pulse Electroconvulsive Therapy Combined With Venlafaxine on Insomnia Symptoms in Elderly Depressed Patients. 
  • Effects of a psychostimulant drug sydnocarb on rat brain dopaminergic transmission in vivo. 
  • Effects of amphetamines and small related molecules on recovery after stroke in animals and man. 
  • Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. 
  • Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity. 
  • Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial. 
  • Effects of electroconvulsive therapy in adolescents with severe endogenous depression resistant to pharmacotherapy. 
  • Effects of exercise training on older patients with major depression. 
  • Effects of fluoxetine treatment in young children with idiopathic autism. 
  • Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. 
  • Efficacy and safety of St. John's wort for the treatment of major depression. 
  • Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. 
  • Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. 
  • Efficacy of Cognitive-Behavioral Therapy for Insomnia Combined With Antidepressant Pharmacotherapy in Patients With Comorbid Depression and Insomnia: A Randomized Controlled Trial. 
  • Efficacy of antidepressants: bias in randomized clinical trials and related issues. 
  • Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. 
  • Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. 
  • Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. 
  • Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness. 
  • Efficient trial designs to reduce placebo requirements. 
  • Electroconvulsive therapy: how effective is it? 
  • Elevation in plasma Abeta42 in geriatric depression: a pilot study. 
  • Emergence of anxiety-like behaviours in depressive-like Cpe(fat/fat) mice. 
  • Emergent anxiety after antidepressant initiation: a retrospective cohort study of Veterans Affairs Health System patients with depression. 
  • Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. The ENRICHD investigators. 
  • Escitalopram for the treatment of major depressive disorder in youth. 
  • Ethnic differences in the treatment of depression in patients with ischemic heart disease. 
  • Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. 
  • Evidence-based treatment of psychiatric disorders with comorbid medical illnesses: the need for large simple clinical trials. 
  • Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review. 
  • Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. 
  • Exercise and pharmacotherapy in patients with major depression: one-year follow-up of the SMILE study. 
  • Exercise and pharmacotherapy in the treatment of major depressive disorder. 
  • Exercise fails to improve neurocognition in depressed middle-aged and older adults. 
  • Exercise therapy for depression in middle-aged and older adults: predictors of early dropout and treatment failure. 
  • Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. 
  • FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications. 
  • Factors associated with antidepressant, anxiolytic, and other psychotropic medication use to treat psychiatric symptoms in the city of São Paulo, Brazil. 
  • Factors influencing variation in prescribing of antidepressants by general practices in Scotland. 
  • Family history of depression and therapeutic outcome: findings from STAR*D. 
  • Feasibility, safety, acceptability, and preliminary efficacy of measurement-based care depression treatment for HIV patients in Bamenda, Cameroon. 
  • Fiber tract-specific white matter lesion severity Findings in late-life depression and by AGTR1 A1166C genotype. 
  • First-line pharmacotherapy approaches for generalized anxiety disorder. 
  • Five potential therapeutic agents as antidepressants: a brief review and future directions. 
  • Focus on CaMKII: a molecular switch in the pathophysiology and treatment of mood and anxiety disorders. 
  • Folate metabolism genes, dietary folate and response to antidepressant medications in late-life depression. 
  • Follow-up visits by provider specialty for patients with major depressive disorder initiating antidepressant treatment. 
  • Frequency of high-risk use of QT-prolonging medications. 
  • Frontal white matter anisotropy and antidepressant remission in late-life depression. 
  • Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. 
  • Functioning and interpersonal relationships as predictors of response in treatment-resistant depression. 
  • Further studies on platelet serotonin transporter binding in depression. 
  • Gender differences in antidepressant and activating drug effects on self-perceptions. 
  • Gender, depressive subtypes, and gender-age effects on antidepressant response: hormonal hypotheses. 
  • Generalized anxiety disorder. An important clinical concern. 
  • Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. 
  • Genetic association study of individual symptoms in depression. 
  • Genetic prediction of antidepressant drug response and nonresponse in Korean patients. 
  • Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. 
  • Goodness-of-fit tests for GEE modeling with binary responses. 
  • Health status and depression remission in patients with chronic heart failure: patient-reported outcomes from the SADHART-CHF trial. 
  • Heat-shock protein-70 genes and response to antidepressants in major depression. 
  • Hippocampal volume and antidepressant response in geriatric depression. 
  • Hippocampal-dependent antidepressant-like activity of histone deacetylase inhibition. 
  • Hippocampus atrophy and the longitudinal course of late-life depression. 
  • Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. 
  • Hypothalamic dysfunction and antidepressant drugs. 
  • I-CARE randomized clinical trial integrating depression and acute coronary syndrome care in low-resource hospitals in China: Design and rationale. 
  • Identifying depression in primary care: a literature synthesis of case-finding instruments. 
  • Identifying serotonergic mechanisms underlying the corticolimbic response to threat in humans. 
  • Impact of a depression care management program for hospitalized cardiac patients. 
  • Impact of hospital type II violent events: use of psychotropic drugs and mental health services. 
  • Impact of pain on the outcomes of depression treatment: results from the RESPECT trial. 
  • Impacts of depression and emotional distress on cardiac disease. 
  • Impaired cholecystokinin secretion in bulimia nervosa. 
  • Improvement in quality of life with left prefrontal transcranial magnetic stimulation in patients with pharmacoresistant major depression: acute and six month outcomes. 
  • Improvements in Depression and Changes in Fatigue: Results from the SLAM DUNC Depression Treatment Trial. 
  • Improving Depression Among HIV-Infected Adults: Transporting the Effect of a Depression Treatment Intervention to Routine Care. 
  • Improving depression care for older, minority patients in primary care. 
  • Improving depression outcomes in older adults with comorbid medical illness. 
  • Improving primary care for depression in late life: the design of a multicenter randomized trial. 
  • Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. 
  • Increased tonic activation of rat forebrain 5-HT(1A) receptors by lithium addition to antidepressant treatments. 
  • Indicators of anxiety and depression in women with the fragile X premutation: assessment of a clinical sample. 
  • Influence of BDNF variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. 
  • Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. 
  • Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. 
  • Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. 
  • Inpatient and outpatient patterns of psychotropic drug prescribing by nonpsychiatrist physicians. 
  • Insight and treatment outcome in obsessive-compulsive disorder. 
  • International consensus statement on major depressive disorder. 
  • International prescribing patterns for mood illness: the International Mood Network (IMN). 
  • Intravenous Ketamine Relieves Pain and Depression After Traumatic Suicide Attempts: A Case Series. 
  • Investigation of possible epistatic interactions between GRIA2 and GRIA4 variants on clinical outcomes in patients with major depressive disorder. 
  • Is mifepristone useful in psychotic depression? 
  • Is there a definition of remission in late-life depression that predicts later relapse? 
  • Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials. 
  • Knockout of the norepinephrine transporter and pharmacologically diverse antidepressants prevent behavioral and brain neurotrophin alterations in two chronic stress models of depression. 
  • L-tryptophan as an antidepressant. 
  • Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. 
  • Late-life depression: how to treat patients with comorbid chronic illness. Interview by Alice V. Luddington. 
  • Lessons from SADHART, ENRICHD, and other trials. 
  • Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. 
  • Lobar distribution of lesion volumes in late-life depression: the Biomedical Informatics Research Network (BIRN). 
  • Long-term use of narcotic/antidepressant medication in the management of phantom limb pain. 
  • Major depression, antidepressant use, and male and female fertility. 
  • Major depressive disorder treatment guidelines in America and Europe. 
  • Management of depression in patients with coronary heart disease: association, mechanisms, and treatment implications for depressed cardiac patients. 
  • Marked differences in antidepressant use by race in an elderly community sample: 1986-1996. 
  • Measurement of depression treatment among patients receiving HIV primary care: Whither the truth? 
  • Medication adherence in combat veterans with traumatic brain injury. 
  • Meeting the needs of primary care physicians: a guide to content for programs on depression. 
  • Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders. 
  • Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial. 
  • Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. 
  • Milnacipran: beyond a role of antidepressant. 
  • Mind the Gap: Gaps in Antidepressant Treatment, Treatment Adjustments, and Outcomes among Patients in Routine HIV Care in a Multisite U.S. Clinical Cohort. 
  • Minor depression and physical outcome trajectories in heart failure and pulmonary disease. 
  • Mixed depression: a study of its phenomenology and relation to treatment response. 
  • Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. 
  • Mood disorders and chronic obstructive pulmonary disease: current research and future needs. 
  • N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. 
  • National trends in antidepressant medication treatment among publicly insured pregnant women. 
  • Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence. 
  • Neural mechanisms of cognitive reappraisal in remitted major depressive disorder. 
  • Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy. 
  • Neurocognitive correlates of response to treatment in late-life depression. 
  • New Developments in Insomnia Medications of Relevance to Mental Health Disorders. 
  • New concepts in the diagnosis and management of depression. 
  • New frontiers in cardiovascular behavioral medicine: comparative effectiveness of exercise and medication in treating depression. 
  • Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. 
  • Nonpharmacologic treatments for depression in patients with coronary heart disease. 
  • One-year change in anterior cingulate cortex white matter microstructure: relationship with late-life depression outcomes. 
  • Onset of alcohol or substance use disorders following treatment for adolescent depression. 
  • Outpatient utilization patterns of integrated and split psychotherapy and pharmacotherapy for depression. 
  • Oxidative/nitrosative stress and antidepressants: targets for novel antidepressants. 
  • PC-FACS. 
  • Pain and palliative care pharmacotherapy literature summaries and analyses. 
  • Panic disorder: making clinical sense of the latest research. 
  • Parental marital discord and treatment response in depressed adolescents. 
  • Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research: Implementing the patient-driven research paradigm to aid decision making in stroke care. 
  • Pediatric pain syndromes and management of pain in children and adolescents with rheumatic disease. 
  • Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. 
  • Pharmacotherapy of depression in pregnancy. 
  • Pharmacotherapy of generalized anxiety disorder. 
  • Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder. 
  • Phosphorylation of MeCP2 at Ser421 contributes to chronic antidepressant action. 
  • Physician office visits of adults for anxiety disorders in the United States, 1985-1998. 
  • Plasma omega-3 polyunsaturated fatty acids and survival in patients with chronic heart failure and major depressive disorder. 
  • Post-traumatic stress disorder: an evaluation of existing pharmacotherapies and new strategies. 
  • Posttraumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment. 
  • Potential antidepressant and resilience mechanism revealed by metabolomic study on peripheral blood mononuclear cells of stress resilient rats. 
  • Potential effects of common drugs on stroke recovery. 
  • Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. 
  • Predictors of antidepressant use among older adults: have they changed over time? 
  • Predictors of depression outcomes in medical inpatients with chronic pulmonary disease. 
  • Predictors of depression recovery in HIV-infected individuals managed through measurement-based care in infectious disease clinics. 
  • Predictors of recurrence in remitted late-life depression. 
  • Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS). 
  • Prefrontal neuropsychological predictors of treatment remission in late-life depression. 
  • Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study. 
  • Presence of neuroticism and antidepressant remission rates in late-life depression: results from the Neurobiology of Late-Life Depression (NBOLD) study. 
  • Prevalence of depression and its treatment in an elderly population: the Cache County study. 
  • Primary care physicians' and psychiatrists' approaches to treating mild depression. 
  • Problems with diagnostic criteria for depression. 
  • Progression of subcortical ischemic disease from vascular depression to vascular dementia. 
  • Provider characteristics related to antidepressant use in older people. 
  • Providers' attitudes towards treating depression and self-reported depression treatment practices in HIV outpatient care. 
  • Psychological discomfort and mental illness in patients with AIDS: implications for home care. 
  • Psychopharmacological treatment for very young children: contexts and guidelines. 
  • Psychosocial and clinical predictors of unipolar depression outcome in older adults. 
  • Psychotropic drug use in late life: a diverse look at an expanding field. 
  • Psychotropic drugs on general medical and surgical wards of a teaching hospital. 
  • Public attitudes towards the acceptability of using drugs to treat depression and ADHD. 
  • QTc prolongation, torsades de pointes, and psychotropic medications. 
  • Quetiapine XR: current status for the treatment of major depressive disorder. 
  • Quetiapine augmentation for depression: dosing pattern in routine practice. 
  • RU486 in depression. 
  • Racial differences in antidepressant treatment preceding suicide in a Medicaid population. 
  • Radiologic correlates of antidepressant-induced delirium: the possible significance of basal-ganglia lesions. 
  • Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. 
  • Rational treatment choices for non-major depressions in primary care: an evidence-based review. 
  • Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. 
  • Recent advances in poststroke depression. 
  • Recent developments and controversies in depression. 
  • Recognition and treatment of depression and anxiety in patients with acute myocardial infarction. 
  • Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. 
  • Relapse of depression after electroconvulsive therapy. 
  • Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia. 
  • Relationship of pharmaceutical promotion to antidepressant switching and adherence: a retrospective cohort study. 
  • Religiosity and remission of depression in medically ill older patients. 
  • Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson Trauma Scale, Clinical Global Impressions and the Clinician-Administered PTSD scale. 
  • Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. 
  • Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. 
  • Response characteristics to antidepressants and placebo in post-traumatic stress disorder. 
  • Response inhibition predicts poor antidepressant treatment response in very old depressed patients. 
  • Risk factors for positive depression screens in hospitalized cardiac patients. 
  • Rubidium and lithium: opposite effects on amine-mediated excitement. 
  • Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. 
  • Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. 
  • Sampling of empirically supported psychological treatments from health psychology: smoking, chronic pain, cancer, and bulimia nervosa. 
  • Scopolamine sleep treatment in private practise. 
  • Seizures and bupropion: a review. 
  • Selective inhibitors of the FK506-binding protein 51 by induced fit. 
  • Serotonin transporter gene polymorphism and antidepressant response. 
  • Sertraline for treatment of depression in acute coronary syndromes. 
  • Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. 
  • Sertraline in children and adolescents with social anxiety disorder: an open trial. 
  • Sexual functioning of men and women with severe obesity before bariatric surgery. 
  • Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial. 
  • Social anxiety disorder in children and adolescents: epidemiology, diagnosis, and treatment. 
  • Social phobia: biological aspects and pharmacotherapy. 
  • Social support and locus of control as predictors of adherence to antidepressant medication in an elderly population. 
  • Sociotropy and autonomy: relationship to antidepressant drug treatment response and endogenous-nonendogenous dichotomy. 
  • Special aspects of neuropsychiatric illness in women: with a focus on depression. 
  • Speed of response to electroconvulsive therapy compared with ketamine. 
  • Spousal depression, anxiety, and suicide after myocardial infarction. 
  • Stress-induced muscle and cutaneous hyperalgesia: differential effect of milnacipran. 
  • Structural brain changes as biomarkers and outcome predictors in patients with late-life depression: a cross-sectional and prospective study. 
  • Successful recruitment strategies for women in postpartum mental health trials. 
  • Suicidality as a possible side effect of antidepressant treatment. 
  • Suicide risk analysis among patients assigned to psychotropics and placebo. 
  • Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. 
  • T-lymphocyte CREB as a potential biomarker of response to antidepressant drugs. 
  • TAAR6 variations possibly associated with antidepressant response and suicidal behavior. 
  • Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. 
  • The 5-HT deficiency theory of depression: perspectives from a naturalistic 5-HT deficiency model, the tryptophan hydroxylase 2Arg439His knockin mouse. 
  • The Depression Treatment Cascade: Disparities by Alcohol Use, Drug Use, and Panic Symptoms Among Patients in Routine HIV Care in the United States. 
  • The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder. 
  • The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. 
  • The Treatment for Adolescents With Depression Study (TADS): demographic and clinical characteristics. 
  • The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. 
  • The Use of Antidepressants in Bipolar Depression. 
  • The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. 
  • The changing perspective on chronic insomnia management. 
  • The effect of antidepressant treatment on HIV and depression outcomes: results from a randomized trial. 
  • The effect of antidepressants on fertility. 
  • The effectiveness of depression care management on diabetes-related outcomes in older patients. 
  • The effects of antidepressant medication adherence as well as psychosocial and clinical factors on depression outcome among older adults. 
  • The implications of DSM-III personality disorders for patients with major depression. 
  • The influence of anxiety and depression on outcomes of patients with coronary artery disease. 
  • The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse. 
  • The pharmacologic management of insomnia in patients with HIV. 
  • The relationship between fibromyalgia and major depressive disorder: a comprehensive review. 
  • The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed outpatients. 
  • The sea urchin embryo as a model for mammalian developmental neurotoxicity: ontogenesis of the high-affinity choline transporter and its role in cholinergic trophic activity. 
  • The treatment effectiveness project. A comparison of the effectiveness of paroxetine, problem-solving therapy, and placebo in the treatment of minor depression and dysthymia in primary care patients: background and research plan. 
  • The treatment of primary insomnia. 
  • The underrecognition and undertreatment of depression: what is the breadth and depth of the problem? 
  • The undertreatment of dysthymia. 
  • The use of analgesics in the management of pain in rheumatic diseases. 
  • The use of antidepressants in long-term care and the geriatric patient. Question-and-answer session. 
  • The use of antidepressants in long-term care and the geriatric patient: geriatric psychiatry issues. 
  • The use of pharmacotherapies for smoking cessation during pregnancy. 
  • Thyroid hormones affect recovery from depression during antidepressant treatment. 
  • Time-to-remission from geriatric depression: psychosocial and clinical factors. 
  • Trajectory classes of depression in a randomized depression trial of heart failure patients: a reanalysis of the SADHART-CHF trial. 
  • Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. 
  • Transdermal selegiline. 
  • Treating cognitive impairment in depression: an unmet need. 
  • Treating depression within the HIV "medical home": a guided algorithm for antidepressant management by HIV clinicians. 
  • Treating insomnia in depression: Insomnia related factors predict long-term depression trajectories. 
  • Treatment considerations for patients with neuropathic pain and other medical comorbidities. 
  • Treatment considerations for the depressed geriatric medical patient. 
  • Treatment course with antidepressant therapy in late-life depression. 
  • Treatment of depression in the medically ill. 
  • Treatment of depression--newer pharmacotherapies. 
  • Treatment of depression. 
  • Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. 
  • Treatment of older adults with co-morbid personality disorder and depression: a dialectical behavior therapy approach. 
  • Treatment of post-stroke depression with antidepressants. 
  • Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study--rationale, design, and methodological issues. 
  • Use of antidepressants by nonpsychiatrists in the treatment of medically ill hospitalized depressed elderly patients. 
  • Use of antidepressants for the treatment of psychiatric illnesses. 
  • Use of antidepressants in medically ill older patients. 
  • Use of the light/dark test for anxiety in adult and adolescent male rats. 
  • Vascular nutritional correlates of late-life depression. 
  • Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12-week prospective, open-label, randomized, parallel-group trial. 
  • Vmat2 heterozygous mutant mice display a depressive-like phenotype. 
  • Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. 
  • Weight changes in postpartum women with remitted depression. 
  • White matter and subcortical gray matter lesion volume changes and late-life depression outcome: a 4-year magnetic resonance imaging study. 
  • White matter hyperintensity progression and late-life depression outcomes. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Bradford, Daniel William, Associate Professor of Psychiatry and Behavioral Sciences, Psychiatry & Behavioral Sciences, Social and Community Psychiatry
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Innovation & Entrepreneurship
  • McClintock, Shawn Michael, Adjunct Associate Professor in the Department of Psychiatry and Behavioral Sciences, Psychiatry & Behavioral Sciences, Brain Stimulation and Neurophysiology
  • Nieuwsma, Jason A, Associate Professor in Psychiatry and Behavioral Sciences, Psychiatry & Behavioral Sciences, Social and Community Psychiatry
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology
  • Olsen, Maren Karine, Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Wu, Li-Tzy, Professor in Psychiatry and Behavioral Sciences, Medicine, General Internal Medicine